Moomoo AI 已提取核心訊息
ADIMAB, LLC, a 10% stockholder in Invivyd, Inc., is set to sell 5,000,000 shares of common stock on January 19, 2024. The shares, with an aggregate market value of $19,750,000, were originally acquired on August 6, 2021, through a private acquisition from the issuer. The acquisition was made in cash for a total of 26,687,906 shares. There have been no reported sales of securities by ADIMAB, LLC in the past three months.
ADIMAB, LLC, a 10% stockholder in Invivyd, Inc., is set to sell 5,000,000 shares of common stock on January 19, 2024. The shares, with an aggregate market value of $19,750,000, were originally acquired on August 6, 2021, through a private acquisition from the issuer. The acquisition was made in cash for a total of 26,687,906 shares. There have been no reported sales of securities by ADIMAB, LLC in the past three months.
ADIMAB, LLC是Invivyd, Inc. 10％的股東，定於2024年1月19日出售500萬股普通股。這些股票的總市值爲19,750,000美元，最初於2021年8月6日通過發行人的私下收購收購。此次收購以現金進行，共計26,687,906股。在過去的三個月中，沒有關於ADIMAB, LLC出售證券的報告。
ADIMAB, LLC是Invivyd, Inc. 10％的股東，定於2024年1月19日出售500萬股普通股。這些股票的總市值爲19,750,000美元，最初於2021年8月6日通過發行人的私下收購收購。此次收購以現金進行，共計26,687,906股。在過去的三個月中，沒有關於ADIMAB, LLC出售證券的報告。
有用
沒用